Kalincik, T. Et Al. 2016. Comparison of 5-year treatment outcomes between alemtuzumab versus natalizumab, fingolimod and interferon beta-1a. 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) , (London, Canada), 829-832.

Kalincik, T., Brown, J. W., Robertson, N., Willis, M., Scolding, N., Pearson, O., ... Ziemssen, T.(2016). Comparison of 5-year treatment outcomes between alemtuzumab versus natalizumab, fingolimod and interferon beta-1a . 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) (pp.829-832). London, Canada

Kalincik, T. Et Al. "Comparison of 5-year treatment outcomes between alemtuzumab versus natalizumab, fingolimod and interferon beta-1a," 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Canada, 2016

Kalincik, T. Et Al. "Comparison of 5-year treatment outcomes between alemtuzumab versus natalizumab, fingolimod and interferon beta-1a." 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) , London, Canada, pp.829-832, 2016

Kalincik, T. Et Al. (2016) . "Comparison of 5-year treatment outcomes between alemtuzumab versus natalizumab, fingolimod and interferon beta-1a." 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) , London, Canada, pp.829-832.

@conferencepaper{conferencepaper, author={T. Kalincik Et Al. }, title={Comparison of 5-year treatment outcomes between alemtuzumab versus natalizumab, fingolimod and interferon beta-1a}, congress name={32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)}, city={London}, country={Canada}, year={2016}, pages={829-832} }